Byrd, MD, 455B, OSUCCC, 410 W. efforts to combine currently applied therapeutic antibodies with other biologic and targeted therapies with efficacy in CLL offers the potential to move toward alternative
ROCK inhibitors
Byrd, MD, 455B, OSUCCC, 410 W. efforts to combine currently applied therapeutic antibodies with other biologic and targeted therapies with efficacy in CLL offers the potential to move toward alternative